About: COVID-19 and Sex Differences: Mechanisms and Biomarkers

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 and Sex Differences: Mechanisms and Biomarkers Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 and Sex Differences: Mechanisms and Biomarkers
Creator	Jayachandran, Muthuvel Narang, Kavita Abeykoon, Jithma Garovic, Vesna Ghamrawi, Ranine Gunaratne, Madugodaralalage Haitao, Tu Parashuram, Santosh Suvakov, Sonja Vermunt, Jane
Source	Elsevier; PMC
abstract	Abstract Men are consistently overrepresented in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and COVID (COrona- VIrus-Disease)-19 severe outcomes, including higher fatality rates. These differences are likely due to gender-specific behaviors, genetic and hormonal factors, and sex differences in biological pathways related to SARS-CoV-2 infection. Several social, behavioral and comorbid factors are implicated in the generally worse outcomes in men as compared with women. Underlying biological sex differences and their effects on COVID-19 outcomes, however, have received less attention. The present review summarizes the available literature regarding proposed molecular and cellular markers of COVID-19 infection, their associations with health outcomes, and any reported modification by sex. Biological sex differences characterized by such biomarkers exist within healthy populations and also differ with age- and sex-specific conditions, such as pregnancy and menopause. In the context of COVID-19, descriptive biomarker levels are often reported by sex, but data pertaining to the effect of patient sex on the relationship between biomarkers and COVID-19 disease severity/outcomes are scarce. Such biomarkers may offer plausible explanations for the worse COVID-19 outcomes seen in men. There is the need for larger studies with sex-specific reporting and robust analyses to elucidate how sex modifies cellular and molecular pathways associated with SARS-CoV-2. This will improve interpretation of biomarkers and clinical management of COVID-19 patients by facilitating a personalized medical approach to risk stratification, prevention, and treatment.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1016/j.mayocp.2020.07.024
has license	els-covid
sha1sum (hex)	a4e6b2e8e870f9140538f42f4c146be8d489aa31
schema:url	https://doi.org/10.1016/j.mayocp.2020.07.024
resource representing a document's title	COVID-19 and Sex Differences: Mechanisms and Biomarkers
has PubMed Central identifier	PMC7402208
schema:publication	Mayo Clin Proc
resource representing a document's body	covid:a4e6b2e8e870f9140538f42f4c146be8d489aa31#body_text
is schema:about of	named entity 'Mayo Clinic Proceedings' named entity 'MAYO' named entity 'FOUNDATION' named entity 'PROC' named entity 'Sex' named entity 'Biomarkers' named entity 'Education and Research' named entity 'Mayo Clinic Proceedings' named entity 'TLR7' named entity 'transplanted kidneys' named entity 'anti-arrhythmic' named entity 'immune response' named entity 'neutrophil to lymphocyte ratio' named entity 'gestation' named entity 'hormonal' named entity 'prostate cancer' named entity 'COVID' named entity 'COVID-19' named entity 'anti-hypertensive' named entity 'SARS-CoV-2' named entity 'vasoconstriction' named entity 'thrombi' named entity 'gene expression' named entity 'receptor' named entity 'renal impairment' named entity 'catabolism' named entity 'type 2' named entity 'hormone replacement therapy' named entity 'acute heart failure' named entity 'renin' named entity 'expression levels' named entity 'COVID' named entity 'interleukins' named entity 'morbidity' named entity 'sex-related' named entity 'sex difference' named entity 'genetic differences' named entity 'heart failure' named entity 'chromosomal' named entity 'IL-8' named entity 'ACE2' named entity 'critically ill' named entity 'assisted ventilation' named entity 'plasma' named entity 'RAAS' named entity 'tissue repair' named entity 'SARS-CoV-2' named entity 'biomarkers' named entity 'COVID' named entity 'placental' named entity 'CRP' named entity 'infection' named entity 'SARS-CoV-2' named entity 'biomarkers' named entity 'sex hormones' named entity 'COVID' named entity 'preeclampsia' named entity 'cardiovascular' named entity 'infectious agents' named entity 'anti-inflammatory' named entity 'NT-proBNP' named entity 'health outcomes' named entity 'IFN' named entity 'neutrophils' named entity 'androgen deprivation therapy' named entity 'receptor' named entity 'TMPRSS2' named entity 'AST' named entity 'COVID' named entity 'inflammation' named entity 'SARS-CoV2' named entity 'risk factors' named entity 'comorbidities' named entity 'biological sex'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software